Recent advancements in molecular recognition have provided additional diagnostic and treatment approaches for multiple diseases, including autoimmune disorders and cancers. Research investigating how the composition of biological fluids is altered during disease progression, including differences in the expression of the small molecules, proteins, RNAs, and other components present in patient tears, saliva, blood, urine, or other fluids, has provided a wealth of potential candidates for early disease screening; however, adoption of biomarker screening into clinical settings has been challenged by the need for more robust, low-cost, and high-throughput assays. This review examines current approaches in molecular recognition and biosensing for the quantification of biomarkers for disease screening and diagnostic outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389739 | PMC |
http://dx.doi.org/10.1016/j.cobme.2021.100318 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!